SCHEMBL273623

SCHEMBL273623

COc1ccc(C(=O)Nc2ccc(Cl)cc2C(=O)N/N=C/c2cccnc2)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.65
RAB9A P51151 2/20 0.65
PKM P14618 1/20 0.65
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.57
POLB P06746 3/20 0.57
PSMD14 O00487 1/20 0.57
DUSP3 P51452 1/20 0.57
PTPN5 P54829 1/20 0.57
PTPN11 Q06124 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
KDM4E B2RXH2 2/20 0.56
OPRK1 P41145 1/20 0.56
HTT P42858 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
MAPK1 P28482 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
ALDH1A1 P00352 2/20 0.53
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266256 1.00 NPC1 (0.65) NPC1RAB9APKMKMT2AMEN1
SCHEMBL264945 0.90 NPC1 (0.65) NPC1RAB9APKMKMT2AMEN1
SCHEMBL273961 0.90 NPC1 (0.65) NPC1RAB9APKMKMT2AMEN1
SCHEMBL266197 0.87 NPC1 (0.61) NPC1RAB9APKMKMT2AMEN1
SCHEMBL266198 0.87 NPC1 (0.61) NPC1RAB9APKMKMT2AMEN1
SCHEMBL267027 0.87 RAB9A (0.62) NPC1RAB9APKMKMT2AMEN1
SCHEMBL267026 0.87 RAB9A (0.62) NPC1RAB9APKMKMT2AMEN1
SCHEMBL266900 0.86 RAB9A (0.59) NPC1RAB9APKMKMT2AMEN1
SCHEMBL266901 0.86 RAB9A (0.59) NPC1RAB9APKMKMT2AMEN1
SCHEMBL266509 0.85 RAB9A (0.63) NPC1RAB9APKMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 NPC1 115/4885RAB9A 1362/4885PKM 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.